All In Biotech

Drug Trial Radar · NCT06484855

Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome

A Double Blind, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of IBI355 in Patients With Primary Sjogren's Syndrome

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jul 14, 2024

Primary completion

Jun 21, 2025

Study completion Jul 25, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of IBI355 in primary Sjogren's syndrome (pSS) patients. This study also aims to evaluate the anti-Drug antibody after multiple ascending doses of IBI355 in pSS patients.

Conditions

  • Primary Sjögren's Syndrome

Interventions

  • IBI355Drug

    IBI355 IV. Q4W

  • IBI355 placeboDrug

    IBI355 placebo IV. Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events and serious adverse eventsTime frame: up to week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.